Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.35 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.35 |
| ▸ | PADI3 | Q9ULW8 | 2/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.35 |
| ▸ | PADI2 | Q9Y2J8 | 2/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051989 | 0.83 | ALDH1A1 (0.41) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL4056294 | 0.82 | LMNA (0.41) | HKDC1PADI1PADI3PADI4PADI2 | |
| SCHEMBL10701726 | 0.79 | PDE10A (0.43) | PAX8MEN1KMT2ATDP1 | |
| SCHEMBL11249957 | 0.77 | MAOA (0.41) | MEN1THRBKMT2ATDP1 | |
| SCHEMBL11273607 | 0.76 | KDM4E (0.44) | CDC25BTDP1 | |
| SCHEMBL2197993 | 0.76 | MAOA (0.53) | CDC25BTDP2NSD2PAX8ABL1 | |
| SCHEMBL1919127 | 0.75 | CCNB2 (0.37) | CDC25BTDP2NSD2PAX8ABL1 | |
| SCHEMBL3520803 | 0.74 | AKR1B1 (0.44) | — | |
| SCHEMBL577689 | 0.71 | TDP1 (0.42) | CDC25BTDP2NSD2PAX8ABL1 | |
| SCHEMBL11813909 | 0.69 | MAOA (0.59) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | CDC25B 3923/4885HKDC1 4012/4885PADI1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.